Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women ...Middle East

-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for the prevention of chlamydia and gonorrhea -- SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- Evofem...

Read More Details
Finally We wish PressBee provided you with enough information of ( Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women )

Also on site :

• Legendary Hard Rock Band Racks Up the Heavy Metal as Iconic Album Hits Sales of 20 Million
• 7UP Confirms Return of Limited-Edition Flavor That Once Flew Off Shelves
• 'Days of Our Lives' Alum Has Fans 'Crying' Over Photo During 'Last Father Daughter Dance'